Technical Analysis for RDHL - Redhill Biopharma Ltd.

Grade Last Price % Change Price Change
grade B 7.65 -0.26% -0.02
RDHL closed down 0.26 percent on Friday, September 13, 2019, on 81 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical RDHL trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
20 DMA Support Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Down 3 Days in a Row Weakness 0.00%
Calm After Storm Range Contraction -3.53%
180 Bullish Setup Bullish Swing Setup -4.61%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.61%
Outside Day Range Expansion -4.61%
Overbought Stochastic Strength -4.61%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.55%

Older signals for RDHL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
Medicine Biopharmaceutical Autoimmune Diseases Antibiotics Inflammatory Bowel Disease Heart Failure Hypertension Abdominal Pain Gastroenterology Bacteria Crohn's Disease Nausea Vomiting Treatment Of Inflammatory Bowel Disease Treatment Of Hypertension Ventricular Dysfunction
Is RDHL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.57
52 Week Low 5.13
Average Volume 75,763
200-Day Moving Average 7.5183
50-Day Moving Average 7.2767
20-Day Moving Average 7.5593
10-Day Moving Average 7.939
Average True Range 0.324
ADX 24.81
+DI 25.4972
-DI 22.1304
Chandelier Exit (Long, 3 ATRs ) 7.328000000000001
Chandelier Exit (Short, 3 ATRs ) 7.572
Upper Bollinger Band 8.4211
Lower Bollinger Band 6.6975
Percent B (%b) 0.55
BandWidth 22.801053
MACD Line 0.2153
MACD Signal Line 0.2191
MACD Histogram -0.0037
Fundamentals Value
Market Cap 131.29 Million
Num Shares 17.2 Million
EPS -2.46
Price-to-Earnings (P/E) Ratio -3.11
Price-to-Sales 264.36
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.92
Resistance 3 (R3) 7.91 7.81 7.88
Resistance 2 (R2) 7.81 7.74 7.82 7.86
Resistance 1 (R1) 7.73 7.70 7.68 7.74 7.84
Pivot Point 7.63 7.63 7.61 7.64 7.63
Support 1 (S1) 7.55 7.56 7.50 7.56 7.46
Support 2 (S2) 7.45 7.52 7.46 7.44
Support 3 (S3) 7.37 7.45 7.43
Support 4 (S4) 7.38